A Phase I Study to Assess the Safety, Tolerability and PK of Ceftazidime-Avibactam in Healthy Chinese Subjects
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
Investigate the safety and tolerability, as well as PK profile of ceftazidime-avibactam (CAZ
-AVI) administered in single and repeated intravenous (IV) infusions in healthy Chinese
subjects.This study data will be used to support CAZ-AVI NDA in China.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca Pfizer
Treatments:
Avibactam Avibactam, ceftazidime drug combination Ceftazidime